Myeloproliferative Neoplasms News

ASH selected 12 fellows to receive awards designed to encourage careers in academic hematology by providing protected research time during training.

ASCO today issued a position statement that proposes a wide range of cost-cutting strategies that can be tested to help lower drug costs based on a standard definition of value.

C. Randal Mills, PhD, has been named CEO of Be The Match, a nonprofit organization that helps patients who need marrow or cord blood transplants.

ASH selected three resident physicians to participate in the 2017 ASH Minority Resident Hematology Award Program.

Cancer death rates appeared higher in rural than urban areas despite lower overall cancer incidence in rural areas, according to data from the CDC published in Morbidity and Mortality Weekly Report.

The FDA granted 510(k) clearance to the Halcyon treatment system for use with image-guided volumetric intensity modulated radiotherapy, according to the device’s manufacturer.

The FDA today allowed marketing of a test that can be used with flow cytometry to help detect several types of blood cancer.

Whether the benefits of antithrombotic therapy outweigh the risks in patients with essential thrombocythemia is unclear based on insufficient evidence, according to a systematic review published in Annals of Internal Medicine.

Former Vice President Joe Biden and his wife, Jill Biden, PhD, launched the Biden Cancer Initiative today.

Patients who have clonal hematopoiesis of indeterminate potential in peripheral blood cells had an elevated risk for CHD, according to a study published in The New England Journal of Medicine.